Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol. 1998;25(3):305–14.
2. Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29(1):69–73. https://doi.org/10.1053/ejso.2002.1380.
3. Cavaliere F, Giannarelli D, Valle M, Federici O, Liotta G, Perri P, Di Filippo F, Garofalo A, Ialongo P. Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment. In Vivo. 2009;23(3):441–6.
4. Uzan J, Bonsang-Kitzis H, Rossi L, Rance B, Bats AS, Gosset M, Deloménie M, Pujade-Lauraine E, Lécuru F, Ngô C. Prognostic impact of initial tumor load and intraperitoneal disease dissemination patterns in patients with advanced ovarian cancer undergoing complete cytoreductive surgery. Eur J Surg Oncol. 2019;45(9):1619–24. https://doi.org/10.1016/j.ejso.2019.04.011.
5. Sun JH, Ji ZH, Yu Y, Wu HT, Huang CQ, Zhang Q, Yang XJ, Yonemura Y, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat advanced/recurrent epithelial ovarian cancer: results from a retrospective study on prospectively established database. Transl Oncol. 2016;9(2):130–8. https://doi.org/10.1016/j.tranon.2016.02.002.